ProCE Banner Activity

CE / CME

Whom to Screen for Hepatitis Delta Virus

Multimedia

Learn about the impact of hepatitis delta virus infection on liver disease progression and the potential burden of going undiagnosed.

Nurses: 0.25 Nursing contact hour

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: December 12, 2022

Expiration: December 11, 2023

No longer available for credit.

Share

Faculty

Nancy Reau

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Coleman I. Smith

Coleman I. Smith, MD

Professor of Medicine
Hepatologist
Georgetown Transplant Institute
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Gilead Sciences, Inc.

Partners

AHF

ProCE Banner

Target Audience

This program is intended for physicians, pharmacists, registered nurses, nurse practitioners, and other healthcare professionals who provide care for patients with HBV infection or patients at risk for HBV/HDV infection.

Learning Objectives

  • Recognize the impact of HDV infection on liver disease progression and the potential burden of going undiagnosed
  • Implement screening practices within diverse healthcare settings to maximize identification of patients with HBV/HDV coinfection

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Nancy Reau, MD: consultant/advisor/speaker: AbbVie, Antios, Arbutus, Gilead, Intercept, Salix; research support: AbbVie, Gilead, Intercept.

Coleman I. Smith, MD

Professor of Medicine
Hepatologist
Georgetown Transplant Institute
Georgetown University
Washington, DC

Coleman I. Smith, MD: researcher: AbbVie, Genfit, Gilead.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-304-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 12, 2022, through December 11, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


To improve rates of diagnosis for HDV by providing a simplified algorithm for screening for HBV that incorporates routine testing for delta coinfection and by encouraging systematic testing for delta among patients already diagnosed with HBV.